TG Therapeutics announced its financial results for the second quarter of 2025, reporting total revenue of $141.1 million. This includes U.S. net product revenue for BRIUMVI of $138.8 million, demonstrating continued strong commercial momentum.
The company's net income for Q2 2025 was $28.2 million, or $0.17 per diluted share, which was slightly below the consensus estimate of $0.19 per share. Despite the EPS miss, the robust revenue performance underscores BRIUMVI's growing market adoption.
In light of these results, TG Therapeutics raised its full-year 2025 U.S. net revenue guidance for BRIUMVI to approximately $570-$575 million. The company also highlighted ongoing studies for a subcutaneous formulation and combined Day 1 and Day 15 IV dosing for BRIUMVI, alongside the first patient dosed in a Phase 1 study for azer-cel in progressive MS in August 2025 and exploratory trials for BRIUMVI in Myasthenia Gravis commenced in January 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.